Peripheral T-Cell Lymphoma 
                     Peripheral  T-Cell  Lymphoma  (PTCL):  Overview,  Epidemiology,  Treatment  Market,
Emerging Drugs and Key players
Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop
from mature T-cells and natural killer (NK) cells.
How has Peripheral T-Cell Lymphoma impacted people's lives?
 PTCL accounts for 10–15% of all non-Hodgkin lymphomas worldwide
 The  total  incident  population  of  Peripheral  T-Cell  Lymphoma  (PTCL)  in  7MM was
16,298 in 2017
 The incident population of PTCL in the United States was 6,110; whereas in Germany,
it was 1,183 and in the UK, the number was 1,100 in 2017
 PTCL accounts for 7–15% of NHLs in the United States and EU-5 countries
 PTCL accounts for around 20–25% of NHLs in Japan 
 EU5 countries occupied around 28.48% of the patient pool amongst 7MM in 2017
How will Disease transform PTCL Market?  
The current standard of care for initial   PTCL market   treatment is multi-agent chemotherapy.
The treatment has not significantly changed in decades and is too often unsuccessful in leading
the long-term remissions, underscoring the need for new treatments. The progress will be made
incrementally in the different subtypes. 
With  the  new  insights  into  the  understanding  of  the  PTCL,  future  endeavours  for  PTCL
treatment should focus on developing trials specific for different subtypes, and exploring novel
combination therapies in the front-line setting. 
Apart  from  these  approved  and  off-label  therapies,  various  emerging  therapies  are  being
evaluated in clinical trials for the treatment of PTCL and its subtypes. 
Which biotechnical companies are developing Peripheral T-Cell Lymphoma drugs?
There a slew of biotechnological  companies that are developing  PTCL emerging therapies,
which include Azacitidine (Celgene Corporation), Denileukin diftitox (Eisai), HBI-8000 (HUYA
Bioscience International/Quintiles), COPIKTRA (Verastem), Tislelizumab (BeiGene), Keytruda
(Merck), STI-3031/IMC-001 (Sorrento Therapeutics), SP-02 (Solasia Pharma), Tipifarnib (Kura
Oncology),  ALRN-6924  (Aileron  Therapeutics),  Ruxolitinib  (Incyte),  and  Romidepsin  +
Azacitidine and many others.